Newsletter · · Ashutosh Agarwal

Medicaid Cuts and ACA Erosion Move the Squeeze to the Top Line - Managed Care Under Pressure - Week of September 12, 2026

Managed Care Under Pressure for the week of September 6 to September 12, 2026: a new Health Affairs analysis put $52 billion of Medicaid state-directed-payment cuts on the board with a January 2028 cliff, forced Medicare Advantage disenrollments jumped from a 1% norm to roughly 10% as Humana's CFO pointed to capital returns, ACA marketplace enrollment fell 13% with premiums up 114% for subsidy losers, and employers are bracing for another double-digit cost year while carving out their PBMs.

Managed Care Under Pressure

Week of September 12, 2026: Medicaid Cuts and ACA Erosion Move the Squeeze to the Top Line

TL;DR

  • The pressure this week showed up in enrollment, not just medical costs. Podcasts quantified an erosion happening at the same time across all three government-linked markets these insurers live in: Medicaid, the Affordable Care Act (ACA) exchanges, and Medicare Advantage (MA). Fewer covered members is a revenue story, and it is arriving now.
  • The single most quotable moment: Humana's (HUM) chief financial officer Celeste Mellet was cited saying the company is "increasingly... very much focused on the capital returns of the plan," that is, walking away from members who don't pay. Forced MA disenrollments (when a carrier drops a plan and pushes members out) have reportedly jumped from a 1% average in 2018 to 2024 to about 10% this year.

What's new

1. The $1 trillion Medicaid cut just got a concrete, state-by-state price tag. On A Health Podyssey, host Rob Lott (Health Affairs) interviewed Deborah Lipson, a health-policy analyst who spent two decades as a senior fellow at the research firm Mathematica. She walked through her new September paper in Health Affairs on one specific piece of last year's budget law: the limits on "state-directed payments," or SDPs.

In plain terms: SDPs are a mechanism where a state tells its Medicaid managed-care plans (like those run by Centene, Molina or Elevance) to pay hospitals and doctors more than the low baseline Medicaid rate, and the federal government matches much of that extra spending. It became huge. Lipson said the number of SDPs "tripled" from about 120 in 2018 to more than 300 in 2024, and the dollars tripled from roughly $27 billion in 2020 to nearly $98 billion in federal fiscal year 2024, going from 4% to 12% of all Medicaid spending. The 2025 budget law (H.R.1, the "One Big Beautiful Bill Act") caps those payments at roughly Medicare rates. Her findings: the change is "likely to decrease Medicaid spending 10 to 25 percent in 17 states," with about $52 billion that eventually has to be cut, and the Congressional Budget Office scoring the SDP limit alone at $149 billion in federal savings over 10 years, about 15% of the law's full roughly $1 trillion in health cuts. The pain is wildly uneven: Nebraska roughly 38% of Medicaid spending, Louisiana roughly 32%, Tennessee roughly 31%, versus under 1% in Maryland. Payments above Medicare are "grandfathered" only until January 2028, then phased down over five to ten years. A Health Podyssey, "Medicaid Funding Fight: $52 Billion on the Chopping Block" (2026-09-09)

Why it matters: SDP dollars flow through Medicaid managed-care plans on their way to hospitals, so most of the hit lands on providers. But it is the clearest evidence yet that the Medicaid revenue pool CNC, MOH, ELV and UNH swim in is shrinking, and the January 2028 cliff gives a date to watch. It also tightens hospital economics on the other side of the trade.

2. Humana's "shrink to fix" got a number and an operator quote. Paging America, a progressive universal-healthcare advocacy show hosted by campaign strategist Miles Baker and emergency physician Dr. Rob Davidson, flagged data (attributed to the National Committee to Preserve Social Security and Medicare) that forced Medicare Advantage disenrollments averaged just 1% from 2018 to 2024, rose to 6.9% in 2025, and have jumped to about 10% this year, reaching a startling 92% in Vermont. They cited Humana CFO Celeste Mellet saying the company is "increasingly... very much focused on the capital returns of the plan," and noted Humana's targeted 2027 plan exits are expected to affect roughly 600,000 enrollees, the second straight year it has downsized its MA footprint. Paging America, "Mapping the MAHA Movement with The Bulwark's Will Sommer" (2026-09-10)

Why it matters: This puts hard numbers on the "shrink to fix" theme we've tracked for weeks. Carriers are trading membership for margin on purpose. The Mellet quote is the operator saying the quiet part out loud, capital returns over member counts, which supports the bull case on discipline and the bear case on political backlash at the same time.

3. The ACA exchange erosion we've been waiting to see finally showed up. Unfcking The Republic*, a progressive commentary podcast (a pundit essay, but sourcing named research groups), tallied the marketplace damage: effectuated enrollment (people who actually paid and are covered) fell 13% between 2025 and 2026, from a record 22 million to 19 million per KFF, the first decline since the first Trump administration, with KFF projecting a slide toward roughly 17 million by year-end. The driver is the expiration of the enhanced premium tax credits under the same budget law: the average enrollee keeping the same plan saw their premium payment rise 114%. On top of that, the podcast cited a Health System Tracker analysis showing a median proposed 2027 marketplace rate increase of 15%, following an 18% median increase this year, two straight years of double-digit hikes. It also cited CBO projecting 10 million-plus fewer Medicaid enrollees by 2034 (the AMA estimates 11.8 million) and Georgetown's Center for Children and Families finding roughly 2.5 million children have lost Medicaid or CHIP coverage since January 2025. Unf*cking The Republic, "Merchants of Death: The Men Who Killed Healthcare in America." (2026-09-05)

Why it matters: Last week we flagged ACA subsidy expiration and 2027 rate filings as still to come in the podcasts. This week they arrived. A shrinking, pricier exchange pool matters most for CNC and, secondarily, ELV, CVS/Aetna and MOH, and a smaller pool that keeps its sickest members (because healthy people drop coverage when it gets expensive) is an adverse-selection risk on medical costs, not just a revenue hit. (Note: these figures come from an opinion podcast; treat them as the show's characterization of KFF, CBO, AMA and Georgetown data.)

4. Employers are bracing for another double-digit cost year, and PBMs are in the crosshairs. On The Business of Benefits Podcast, host Chelsea Ryckis (Ethos Benefits, a benefits consultant) interviewed Karen van Coll of the Florida Alliance for Healthcare Value, an employer-led coalition. Van Coll cited the National Alliance's newly released "Pulse of the Purchaser" survey: about 40% of members expect health-cost increases of 9% or more, with some projecting 11%, 12%, or 13% next year if they make no plan changes. She named the three biggest affordability threats as hospital prices, high-cost claims (oncology a top driver), and drug prices, singling out that "the GLP-1 situation has taken off." She said the pressure is now mostly price, not utilization, and pointed to Florida hospitals being paid around 345% of Medicare (2020 to 2022 RAND data), running to 500% to 600% in some markets. The recurring theme: employers carving out and auditing their pharmacy-benefit managers (PBMs, the middlemen like CVS's Caremark, Cigna's Express Scripts and UNH's Optum Rx), demanding 100% rebate pass-through, claims-level data and audit rights ahead of transparency rules that become mandatory after August 1, 2028. The Business of Benefits Podcast, "Movements, Not Memberships: Rethinking Employer Health Coalitions" (2026-09-10)

Why it matters: This is the commercial-employer side of the trend, the book that funds Cigna's Evernorth, CVS's Caremark and UNH's Optum Rx. The message is that large employers are getting more aggressive about clawing back PBM economics and scrutinizing GLP-1 and specialty-drug spend, a slow-burn margin risk for the PBM and services arms.

The debate

Bull (the trough is in, discipline pays off into 2027): Carriers are deliberately shedding unprofitable members, Humana's roughly 600,000 planned 2027 MA exits and rising forced-disenrollment rates are a feature, not a bug. Fewer, better-priced members plus 2027 repricing should let margins heal. The CFO focus on "capital returns" is exactly the discipline investors have demanded. On the cost side, the employer podcast this week suggested trend is being driven more by unit price than by runaway utilization, which is somewhat easier to manage through network and benefit design.

Bear (this is a multi-year, government-driven reset): The squeeze is now hitting the revenue line across all three government markets at once. Medicaid funding is being cut ($52 billion of state-directed payments, a January 2028 cliff), the ACA exchange pool is shrinking 13% with premiums up over 100% for subsidy losers, and MA plans are being culled. Shedding members shrinks the earnings base and leaves a sicker residual pool (adverse selection) that can push the medical loss ratio (MLR, the share of premiums paid out as medical claims) the wrong way. Layer on GLP-1 cost pressure and a hostile political backdrop, this week's advocacy podcasts openly called MA "a scam" and floated abolishing it, and the multiple stays capped even if any single quarter looks fine.

Stocks in play

Fresh detail this week is concentrated in HUM (the disenrollment data and CFO quote) and, at the sector level, the Medicaid and exchange names. The rest is the standing setup updated for this week's themes.

  • UNH (UnitedHealth), Bull: biggest, most diversified, Optum services cushion; leader in the disciplined 2027 reset. Bear: Medicaid SDP funding cuts touch its Medicaid book; DOJ MA-coding and audit overhang remains live from prior weeks. Next catalyst: can 2027 bids hold margin without further member loss; any DOJ or RADV coding news.
  • HUM (Humana), Bull: furthest along "shrink to fix," most transparent about prioritizing capital returns. Bear: roughly 600,000 more members exiting in 2027 shrinks the base a second straight year; political target (named repeatedly this week). Next catalyst: whether 2027 is the last leg of the shrink or another down year on membership.
  • CVS (CVS Health / Aetna), Bull: integrated model, Caremark scale. Bear: Caremark squarely in the PBM-transparency and rebate-pass-through crosshairs employers described this week; Aetna exposed to exchange pool shrinkage. Next catalyst: 2027 benefit design; PBM contract and regulatory developments.
  • ELV (Elevance), Bull: diversified across MA, Medicaid and exchanges. Bear: Medicaid book exposed to SDP cuts and enrollment declines; exchange pool erosion. Next catalyst: 2027 Medicaid rate adequacy versus a sicker, smaller pool.
  • CNC (Centene), Bull: disciplined Medicaid and exchange underwriter. Bear: the most exposed name to this week's two biggest policy items, Medicaid SDP and enrollment cuts and the 13% ACA exchange enrollment drop with adverse selection. Next catalyst: state Medicaid rate updates versus acuity; how badly the enhanced-subsidy expiration dents its exchange margins.
  • MOH (Molina), Bull: focused Medicaid specialist. Bear: most levered to Medicaid disenrollment and the SDP funding squeeze; smaller, sicker pool risk. Next catalyst: state rate adequacy versus acuity shift.
  • CI (Cigna), Bull: cleanest of the group on government exposure (little MA), Evernorth growing. Bear: Express Scripts is a prime PBM-reform and employer-carve-out target, exactly the pressure employers described this week. Next catalyst: PBM legislation and employer contract renewals; GLP-1 economics through Express Scripts.

Read-throughs

  • Medicaid and exchange insurers (CNC, MOH, ELV): This was the center of gravity this week. Two independent pressures stacked, the $52 billion state-directed-payment cut (with a January 2028 grandfather cliff) and a 13% drop in ACA marketplace enrollment as enhanced subsidies expired. Smaller pools that keep the sickest members are the classic setup for margin pressure. CNC and MOH carry the most concentrated exposure.
  • PBMs and Optum-style services arms (Caremark/CVS, Express Scripts/CI, Optum Rx/UNH): Employers, via the Florida Alliance, described a growing push to carve out and audit PBMs, demand full rebate pass-through and claims data, and get ahead of transparency rules landing after August 1, 2028. Slow-burn margin risk for the pharmacy and services segments that have been the group's earnings ballast.
  • Hospitals and providers: They sit on the other side of every trade above. State-directed-payment cuts reduce a real funding stream to hospitals serving Medicaid patients; the ACA enrollment drop is already producing "a sharp rise in uninsured patients" (per a July New York Times report cited on Unfcking The Republic*). Bad-debt and payer-mix pressure for the provider complex.
  • GLP-1 cost exposure: Named again this week as a top-three affordability threat by the employer coalition ("the GLP-1 situation has taken off"). No specific new coverage decision by a named insurer this week, but the direction of travel, employers scrutinizing and often excluding these drugs, continues to shift cost off insurer and employer books toward cash-pay and Medicare's temporary bridge.

What changed vs last week

Last week (week of 2026-09-05) was rich on the supply side of 2027: UnitedHealth's plan-design reset (HMOs in, PPOs out), CMS's new enrollment-cap lever, Humana's $542 million Village Health coding settlement, employer GLP-1 drops (PepsiCo, Starbucks), and a walkthrough of the roughly $1 trillion Medicaid cut. This week the lens shifted to the demand and funding side:

  • Advanced: The Medicaid cut theme got specific and quantified, the $52 billion state-directed-payment mechanism, 17 states facing 10% to 25% cuts, a $149 billion CBO score, and the January 2028 cliff. Humana's "shrink to fix" gained hard numbers (forced disenrollments 1% to 6.9% to 10%) and an operator quote (CFO Celeste Mellet on "capital returns"). And the ACA exchange erosion that had not yet surfaced last week finally appeared, enrollment down 13% to 19 million, premiums up 114% for subsidy losers, 2027 rate filings proposed at plus 15%.
  • Not advanced this week: No new UNH DOJ MA-coding update, no RADV audit specifics, no Star-ratings litigation, and no M&A chatter (Optum carveout, CVS strategic review, Humana Medicaid sale). Last week's Humana $542M Village Health settlement and the CMS enrollment-cap lever were not followed up.